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Novel genetically encoded ﬂuorescent probes
enable real-time detection of potassium in vitro and
in vivo
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Changes in intra- and extracellular potassium ion (K+) concentrations control many impor-
tant cellular processes and related biological functions. However, our current understanding
of the spatiotemporal patterns of physiological and pathological K+ changes is severely
limited by the lack of practicable detection methods. We developed K+-sensitive genetically
encoded, Förster resonance energy transfer-(FRET) based probes, called GEPIIs, which enable
quantitative real-time imaging of K+ dynamics. GEPIIs as puriﬁed biosensors are suitable to
directly and precisely quantify K+ levels in different body ﬂuids and cell growth media. GEPIIs
expressed in cells enable time-lapse and real-time recordings of global and local intracellular
K+ signals. Hitherto unknown Ca2+-triggered, organelle-speciﬁc K+ changes were detected in
pancreatic beta cells. Recombinant GEPIIs also enabled visualization of extracellular K+
ﬂuctuations in vivo with 2-photon microscopy. Therefore, GEPIIs are relevant for diverse K+
assays and open new avenues for live-cell K+ imaging.
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Potassium ions (K
+), the most abundant intracellular
cations1, are essential for the proper functioning of all cell
types2. Electrochemical K+ gradients across the plasma
membrane and membranes of organelles allow K+ ﬂuxes to
control a variety of cell functions3. Disturbances of K+ home-
ostasis have profound implications at both cellular and orga-
nismal level and feature in many diseases1, 3 including
neurological, cardio-vascular, renal, immunological, muscle, and
metabolic disorders as well as cancer4. Besides its fundamental
role in membrane potential, K+ is also known to bind directly to
several enzymes and regulate their activity, for example pyruvate
kinase5, 6, diol dehydratase7, fructose 1,6-bisphosphatase8, or
S-adenosylmethionine synthase9. Flux and transport of K+ across
bio-membranes occur via numerous different K+ channels10,
exchangers1, and pumps11, which have emerged as promising
drug targets for a variety of diseases12. However, our present
understanding of extra- and intracellular K+ ﬂuctuations is very
limited due to the lack of sensors that allow investigation of K+
dynamics with high spatial and temporal resolution13. K+-selec-
tive electrodes are often used to quantify K+ in serum, plasma, or
urine and to measure changes in extracellular K+14, but these
electrodes are invasive and not able to measure spatiotemporal
dynamics of K+ variations and intracellular K+ signals. Several
small-molecule ﬂuorescent K+ sensors15 have been developed
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Fig. 1 In vitro characterization of GEPIIs. a Schematic representation of the mechanism of K+ sensing by FRET-based GEPIIs. Predicted conformational
rearrangement of GEPIIs in the absence and presence of K+. b Scheme (upper panel) and spectral properties (lower panel) of CFP and FRET ﬂuorescence of
puriﬁed GEPII 1.0 at increasing K+ concentrations. Puriﬁed GEPII 1.0 was excited at 413.4± 8 nm. c Scheme (upper panel) and emission spectra (lower
panel) of the K+-insensitive lc-BON GEPII 1.0 in vitro. d Schematic overviews of differently mutated and engineered GEPIIs. e Normalized EC50 curves for K
+ of GEPIIs in vitro (n= 4 for each construct). f K+ selectivity of lc-LysM GEPII 1.0 (n= 3 for each ion). FRET ratio signals are plotted against increasing
concentrations of different cations
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with the goal of imaging K+ ﬂuctuations using ﬂuorescence
microscopy. Unfortunately, most of these ﬂuorescent ionic indi-
cators suffer from limited speciﬁcity for K+ and low dynamic
range, are difﬁcult to load into cells, are not selectively targetable
into subcellular compartments and may be toxic. Due to these
severe restrictions, meaningful quantitative ﬂuorescence K+
imaging has been virtually impossible up to now16. Here we
describe the development of a family of genetically encoded
Förster resonance energy transfer- (FRET-) based K+ indicators,
which we have named GEPIIs (Genetically Encoded Potassium
Ion Indicators), and their validation for dynamic quantiﬁcation
of K+ in vitro, in situ, and in vivo. We also present results which
show that GEPIIs can be used successfully for K+ ﬂuorescence
imaging, which will improve our understanding of (sub)cellular
K+ signals and K+-sensitive signaling pathways.
Results
Design and characterization of GEPIIs. Very recently a bacterial
K+-binding protein (Kbp), has been characterized17. Kbp consists
of a K+-binding BON domain and a second lysine motif (LysM),
which are supposed to interact in the presence of K+17. We
decided to explore whether Kbp could be used as the basis of a
FRET-based K+ probe, and fused either wild-type or mutated Kbp
directly with the optimized cyan and yellow FP variants18,
mseCFP and cpV, to the N- and C-terminus, respectively (Fig. 1).
The mseCFP and cpV are approved FPs that have been used for
the generation of many biosensors19–22 due to their high FRET
efﬁciency18 and low tendency to form dimers23. We named these
chimeras GEPIIs, as explained above, and hypothesized that upon
K+ binding to these chimeras, the two terminal FPs would be
closely aligned yielding increased FRET, while in the absence of
the ion, FPs would become separated resulting in reduced FRET
(Fig. 1a). To test this idea, we ﬁrst puriﬁed recombinant GEPII
1.0, containing wild-type Kbp (Fig. 1b, upper panel), and tested
whether K+ addition induced a ﬂuorescence spectral change
in vitro (Fig. 1b, lower panel). As expected, K+ addition increased
the FRET ratio signal of GEPII 1.0 (i.e., decrease of the FRET-
donor mseCFP ﬂuorescence accompanied by an increase in the
FRET signal) in a concentration-dependent manner (Fig. 1b, e).
The half maximal effective concentration (EC50) of GEPII 1.0
was found to be 0.42 (0.37–0.47) mM of K+ in vitro at room
temperature (Fig. 1e). The response of the FRET ratio to K+
covered a 3.2-fold range, which is remarkable high and should,
hence, be sufﬁcient for useful K+ measurements. The high FRET
ratio changes likely reﬂect a dramatic conformational rearran-
gement of Kbp from an elongated to a spherical structure upon
K+ binding which is in line with a recent report17. Values for the
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Fig. 2 Application of puriﬁed GEPII 1.0 to determine K+ levels within biological samples. a Schematic workﬂow of an automatable K+ determination assay. b
Urine [K+] of healthy human donors was determined using GEPII 1.0 in vitro and plotted against [K+] in the same samples determined with ion-selective
electrodes (ISE, n= 15, P= 0.9625, paired t-test). c Bland–Altman plot showing human plasma [K+] of healthy donors (white circles, n= 15) and
hemodialysis patients (red circles, n= 15) determined using ISE and puriﬁed GEPII 1.0, respectively. Bias (black dashed line) and 95% limits of agreement
(red dashed lines) are shown (n= 15, P= 0.6504, paired t-test). d Comparison of individual K+ levels of human plasma samples determined using
recombinant GEPII 1.0 of healthy controls (ctrl, n= 15± SD) and hemodialysis patients (HD-P, n= 15± SD, ***P< 0.0001, unpaired t-test). e [K+] of mouse
urine (n= 11, ±SD), serum (n= 25, ±SD), and bile (n= 7, ±SD) samples quantiﬁed with recombinant GEPII 1.0. f Representative images of periodic acid-
Schiff stained kidney slices of a control mouse (upper panel) and a mouse after ischemia-reperfusion injury (IRI). Scale bar represents 50 µm. Black arrow
indicates a tubular cast; black stars mark dilated tubules with loss of brush borders. g Serum creatinine and serum urea levels of control mice (white bars)
and mice after IRI (blue bars, n= 5 for each, ± SD, ***P< 0.0001, unpaired t-test). h Serum (left columns) and urine (right columns) [K+] of control mice
(white bars, n= 8 for both± SD) and mice after IRI (blue bar and yellow bar, n= 18 for serum, n= 3 for urine± SD, ***P< 0.001, unpaired t-test)
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association rate constant (kon) and dissociation rate constant
(koff) of GEPII 1.0 were found to be 1.19 × 10−1 mM−1 s−1 and
7.53 × 10−1 s−1 (Supplementary Fig. 1a), pointing to the fast on
and off kinetics of the K+ sensor. As expected, the absorption
spectrum of GEPII 1.0 was unaffected by K+ addition (Supple-
mentary Fig. 1b).
Replacement of most acidic amino acids in the BON domain17
by their corresponding amides yielded the K+-insensitive “low-
charge BON” (lc-BON) GEPII 1.0 (Fig. 1c). To generate a series of
functional GEPIIs with lower K+ sensitivity than GEPII 1.0, either
all acidic amino acids within the LysM domain17 were mutated or
ﬂexible linkers of variable lengths (7, 10, or 15 aa) were introduced
between the BON and LysM domains (Fig. 1d and Supplementary
Fig. 2). We hypothesized that in addition to classical mutations the
introduction of variable linkers between the BON and LysM
domain (Supplementary Fig. 2) will affect the K+ sensitivity by
impeding their K+ dependent interaction. These rationally
designed variants, which we named lc-LysM GEPII 1.0, GEPII
2.7, GEPII 2.10, and GEPII 2.15, sensed K+ in vitro with EC50
values of 27.43 (24.38–30.87) mM, 3.24 (2.96–3.55) mM, 4.39
(4.01–4.80) mM, and 8.59 (7.70–9.58) mM at room temperature,
respectively (Fig. 1e, Supplementary Fig. 1c–f and Supplementary
Tables 1 and 2). Analysis of the binding kinetics unveiled that all
GEPIIs bind K+ in a non-cooperative manner with Hill slopes
close to 1 (Supplementary Fig. 3a–e), conﬁrming that one
molecule Kbp binds one K+ ion17. In order to test the reversibility
of puriﬁed GEPII 1.0, the recombinant sensor was immobilized
using agarose. This approach allowed time-laps imaging of the
puriﬁed K+ probe in response to K+ addition and removal and
demonstrated both, the functionality and the reversibility of GEPII
1.0 in an agarose matrix (Supplementary Fig. 3f).
The K+ sensitivity of GEPIIs signiﬁcantly decreased with
increasing temperature (Supplementary Fig. 4a). Taking into
account the temperature dependence of the K+ response, these
probes enable the determination of K+ concentrations ([K+])
from ≥ 0.01 mM up to ≤ 1000 mM. This covers the entire range
of known intra- and extracellular K+ concentrations.
We then performed a series of experiments to further
characterize the usefulness and robustness of the GEPII 1.0 K+
signal. First, we used the temperature dependence of the response
to examine the thermo-stability of recombinant GEPII 1.0. The
FRET ratio signal of the puriﬁed probe was recorded repeatedly at
65 and 25 °C in the presence of K+. On cooling, GEPII 1.0
repeatedly and completely recovered its K+ sensitivity (Supple-
mentary Fig. 4b). Next, we examined the pH dependence of the
FRET ratio signal. The K+ response of GEPII 1.0 was almost
constant from pH 7.0 to 9.0 (Supplementary Fig. 4c), indicating
that the probe can be used at normal intra- and extracellular pH
values24. We then tested the ion selectivity of the high and low
K+-sensitive GEPII 1.0 and lc-LysM GEPII 1.0, separately, testing
Na+, Ca2+, Cs+, Rb+, and ammonium ions (NH4+). The
ﬂuorescence properties of both probes remained virtually
unaffected by Na+ and Ca2+ (Fig. 1f and Supplementary Fig. 4d).
Only higher concentrations of Rb+, Cs+, and NH4+, which all
have an atomic radius similar to K+, moderately increased the
FRET ratio signal of GEPII 1.0 (Supplementary Fig. 4d and
Supplementary Table 1), while the ﬂuorescence emission ratio of
lc-LysM GEPII 1.0 was only inﬂuenced by Rb+ but unaffected by
Cs+ and NH4+ (Fig. 1f and Supplementary Table 1). These
experiments conﬁrmed the high selectivity of GEPIIs for K+ over
Rb+, Cs+, NH4+, Na+, and Ca2+.
Quantiﬁcation of [K+] in body ﬂuids. We investigated whether
recombinant GEPII 1.0 could be used to quantify [K+] in different
biological samples in a fast, reliable, precise, and high-throughput
manner using a conventional multi-well ﬂuorescence plate reader.
We presumed that a GEPII-based K+ assay could be accom-
plished in an automatable two- to three-step process including
sample dilution, mixing with puriﬁed GEPII, and FRET ﬂuori-
metry (Fig. 2a). As a possible further simpliﬁcation, we tested
whether lyophilized GEPII 1.0 could be used. Lyophilized GEPII
1.0 was produced directly in a standard multi-well plate, stored
for 1 week, reconstituted in aqueous solution in the presence of
different K+ levels, and analyzed using a ﬂuorescence plate reader
(Supplementary Fig. 5a). The results showed that recombinant
GEPII 1.0 functionally fully recovered after freeze-drying and
storage (Supplementary Fig. 5a), so that lyophilized GEPII 1.0 can
be used for precise [K+] measurement. An analytical calibration
curve was established for the absolute quantiﬁcation of [K+] with
puriﬁed GEPII 1.0 (Supplementary Fig. 5b). Next, we tested [K+]
measurement with GEPII 1.0 in human urine samples from
healthy adults, compared to the results obtained with an ion-
selective electrode (ISE), the current standard technology for
clinical assays of electrolytes14. The results showed close agree-
ment between the GEPII-based [K+] quantiﬁcation assay and the
standard ISE (Fig. 2b and Supplementary Fig. 5c), demonstrating
the accuracy and precision of the new method. Measurements of
human plasma samples from healthy individuals and hemodia-
lysis patients (HD-P) (Fig. 2c and Supplementary Fig. 5d), also
agreed closely with ISE results, showing that GEPII 1.0 is func-
tional, applicable, and precise in human plasma. As expected,
plasma [K+] was signiﬁcantly higher in HD-P than in healthy
controls (Fig. 2d). To test the stability of GEPII 1.0 in human
urine and plasma, the same samples were analyzed immediately
or 4 h after adding the probe to the samples. The values obtained
were virtually identical after 4 h (Supplementary Fig. 5e),
demonstrating the stability of the assay.
Due to the high K+ sensitivity of GEPII 1.0, this assay requires
only very small sample volumes (1–5 µl). To further test the
practicability of the method with small samples, we then used
GEPII 1.0 to determine [K+] in single drops of murine blood,
collected without the need to sacriﬁce the animals. Serum [K+] of
standard laboratory mice was found to be
6.52± 0.76 mM (n= 25, ±SD) with no signiﬁcant difference
between samples collected from the facial vein and the orbital
sinus (Supplementary Fig. 6a). This value agrees well with
published data25. We also determined [K+] levels in urine and bile
of individual mice using recombinant GEPII 1.0 (Fig. 2e),
showing that the probe can be used in different body ﬂuids with
variable [K+]. The GEPII 1.0 probe also proved stable in murine
serum and urine samples for 4 h (Supplementary Fig. 6b). To
further challenge and exploit the GEPII-technology we used a
mouse model of kidney dysfunction, using surgically inﬂicted
renal ischemia-reperfusion injury (IRI)26. Histological analysis
revealed clearly pathological structures of tubular casts with a loss
of brush borders and cell nuclei—features of severe renal injury26
—in comparison to controls (Fig. 2f and Supplementary Fig. 6c).
Classical clinical parameters of renal function such as serum
creatinine and serum urea levels (Fig. 2g) as well as serum
neutrophil gelatinase-associated lipocalin (Supplementary Fig. 6d)
were also increased, demonstrating that the method did in fact
cause manifest kidney injury26. We then applied the GEPII-
technology to quantify [K+] in serum and urine of mice with IRI
and controls. These measurements clearly revealed increased
serum and decreased urine [K+] in mice with IRI compared to
controls (Fig. 2h). Importantly, the samples did not show any
differences in hemolysis (Supplementary Fig. 6e), so that the
increased [K+] in mice with IRI can be attributed to kidney
dysfunction rather than release of K+ from erythrocytes.
Time-lapse [K+]ex determination as cell viability assays. Vital
cells maintain a steep [K+] gradient across the plasma membrane,
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with a ratio of intracellular to extracellular [K+] ([K+]i: [K+]ex) of
≥ 201. Since this gradient is maintained mainly via the
sodium–potassium adenosine triphosphatase (Na+/K+-ATPase)11,
which is strictly energy dependent27, defects in cellular energy
metabolism, are generally accompanied by a loss of this K+
gradient28, with a rise of [K+]ex (Fig. 3a, left); a situation that often
precedes cell death28. Vice versa, in a closed system such as a cell
culture, it can be expected that as cells proliferate they capture
increasing amounts of K+ so that the [K+] concentration in the cell
culture medium ([K+]ex) decreases in proportion to the cell mass1
(Fig. 3a, right). Monitoring [K+] in cell culture media could be a
useful indicator of dynamic cell viability, cell death, and cell
proliferation. We therefore tested whether recombinant GEPII 1.0
could be used to follow [K+] in cultures over periods of several
hours. We did this ﬁrst with INS-1 cells, a pancreatic beta-cell
line29. Cells were kept in the presence of glucose or its cytotoxic
antimetabolite 2-deoxyglucose30 (2-DG) and [K+]ex was measured
over time using puriﬁed GEPII 1.0 (Fig. 3b). While [K+]ex
remained almost constant in the presence of glucose, it gradually
increased in the presence of 2-DG (Fig. 3b), pointing to the
breakdown of the cellular K+ gradient, an expected consequence of
the severe cellular energy crisis and cell death caused by the
cytotoxic glycolysis inhibitor30. At the end of this experiment cells
were treated with digitonin, which increased [K+]ex in the medium
of control cells to similar levels as obtained by 2-DG treatment
(Fig. 3b), conﬁrming the presence of the same cell numbers under
both conditions. If we assume that all cells of the same type have a
similar [K+]i1, the GEPII-based [K+]ex assay with permeabilized
cells could be used to estimate total cell numbers. We investigated
the correlation between cell number and [K+]ex increase upon cell
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Fig. 3 Application of puriﬁed GEPII 1.0 to determine cell viability and cell growth. a Scheme demonstrating cellular K+ loss upon cell death (left arrow) or K+
uptake of proliferating cells (right arrow). b [K+] over time determined with GEPII 1.0 within the supernatant of INS-1 cells cultured either in the presence of
10mM glucose (white circles and black line, n= 6± SD) or 10mM 2-deoxyglucose (red squares and line, n= 6± SD). As indicated, 50 µM digitonin was
applied after 14 h. *P= 0.0178, ***P< 0.0005, unpaired t-test. c Representative FRET ratio signals over time of recombinant GEPII 1.0 within the
supernatant of HeLa cells (upper red curve) were recorded simultaneously with morphological alterations (cell shrinkage) of cells (lower blue curve) on an
inverted ﬂuorescence microscope. As indicated, 30 µM digitonin was added to induce cell necrosis. d [K+] of cell culture medium over time determined
with puriﬁed GEPII 1.0 (red circles, n= 5± SD, *P= 0.05, ***P< 0.005, one-way ANOVA test with Tukey’s Multiple Comparison Test) during bacterial (E.
coli) proliferation. Cell density was recorded in parallel by measuring the optical density at 600 nm (OD600, white circles, n= 5± SD). As indicated
[K+]ex and OD600 were determined after heating of the cells (75 °C for 1 h). e Increases of bacterial cell numbers (ΔCell number) were plotted against the
respective decreases of the extracellular K+ concentrations (Δ[K+]ex)
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permeabilization, and, as expected, found a strict linear correlation
between both parameters (Supplementary Fig. 7a).
To further demonstrate the broad applicability of puriﬁed
GEPII 1.0, morphological alterations of necrotic cells and [K+]ex
were co-imaged using a conventional ﬂuorescence wide-ﬁeld
microscope (Supplementary Fig. 7c). The highly sensitive GEPII
1.0 was suitable to dynamically quantify rises of [K+]ex prior to
detectable changes in the cell morphology of HeLa cells getting
necrotic (Fig. 3c and Supplementary Movie 1). Similar results
were obtained using other cell types, while the amplitude and
plateau of the [K+]ex signal correlated with the cell conﬂuence
(Supplementary Fig. 7b, c and Supplementary Movie 2). Further-
more, we used GEPII 1.0 to quantify the reduction of [K+]ex
during bacterial cell proliferation in simple shake ﬂasks. Our data
unveiled that during the exponential phase of bacterial growth
[K+]ex gradually decreased from 10.2 mM to 9.4 mM within the
culture media (Fig. 3d). Interestingly, these experiments showed
the correlation between increasing bacterial cell number and
decreasing [K+]ex (Fig. 3e), a relationship, which might be highly
cell-type speciﬁc and relevant for optimizing bacteria growth
conditions. Heating of the bacteria to release the intracellular
K+ increased [K+]ex back to ≥ 10 mM (Fig. 3d) and resulted in
positive PI-staining (Supplementary Fig. 7d), indicating
pronounced permeabilization. Short-time treatment of bacteria
with ampicillin also increased PI ﬂuorescence in contrast to other
antibiotics (Supplementary Fig. 7d). However, all antibiotics
tested yielded in signiﬁcant bacterial K+ release, which could be
detected with GEPII 1.0 (Supplementary Fig. 7e). Microorganisms
are typically cultured on agar plates. Thus, we tested the
functionality of GEPII 1.0 under such conditions. GEPII 1.0
embedded into agar–agar was able to report different predeﬁned
(Supplementary Fig. 7f) as well as dynamically manipulated [K+]
(Supplementary Fig. 7g) in the gelatinous matrix. These
experiments demonstrate that recombinant GEPIIs are suitable
to visualize K+ alterations both, in liquid media and agar.
Testing the functionality of GEPII 1.0 in vivo. To test the
suitability of GEPIIs in vivo, recombinant GEPII 1.0 was loaded
into the exposed striated muscle (musculus cremaster) of a mouse
(Fig. 4a). Tissue loading was achieved by incubation with GEPII
1.0 for 20 min. Intravital microscopy showed that GEPII 1.0
diffused deep into the cremaster muscle without entering blood
vessels, accumulating in the interstitial spaces (Supplementary
Fig. 8). The ﬂuorescence signals remained stable in this experi-
mental setup, indicating that the recombinant protein probe was
stable when applied in vivo. To test the functionality of GEPII 1.0
in the muscle, [K+]ex was manipulated by the addition and
removal of KCl (Fig. 4b, c). Increasing [K+] signiﬁcantly increased
the FRET ratio signal of recombinant GEPII 1.0 at different tissue
depths, while the washout of K+ reduced the signals (Fig. 4b). The
FRET ratio decrease upon K+ washout was slower in deeper tissue
(Fig. 4b) and faster in more superﬁcial tissue. These results
demonstrate the feasibility of using GEPIIs to monitor spatial and
temporal patterns of [K+]ex changes in vivo.
Quantiﬁcation of intracellular [K+] of living cells. The other
major use of GEPIIs we wanted to test was monitoring of K+
inside cells by microscopic imaging. We did this using cells
expressing GEPIIs and manipulated [K+]i by treating the cells
with digitonin or gramicidin to permeabilize the plasma mem-
brane. The FRET ratio signal of GEPIIs gradually decreased in the
absence of extracellular K+ (Supplementary Fig. 9a), reﬂecting
initially high cytosolic [K+] being dissipated by these agents.
Permeabilized cells were then treated with different [K+]ex, which
dynamically affected mseCFP (FRET donor) and FRET acceptor
ﬂuorescence intensities (Fig. 5a, b); this showed that that GEPIIs
indicate changes of [K+]i reversibly and in a ratiometric manner.
The respective changes of FRET ratio signals were induced by
adding and removing K+ either in a cumulative (Fig. 5b and
Supplementary Fig. 9b) or repetitive manner (Supplementary
Fig. 9c) to determine EC50 values and K+ selectivity of GEPIIs in
cells (Fig. 5c and Supplementary Fig. 9d, Supplementary Table 2).
As under physiological conditions K+ and Na+ are the pre-
dominant ions1, 6, we next investigated whether or not the pre-
sence of Na+ at concentrations ranging from 0 mM to 150 mM
impact on K+ sensing. Even strong Na+ ﬂuctuations did not
signiﬁcantly inﬂuence the FRET ratio signals of GEPII 1.0 in
response to K+ of permeabilized HeLa cells (Supplementary
Fig. 10).
We then investigated whether the FRET-based K+ sensors
could detect possible variations of [K+]i between distinct cellular
compartments. To do this, GEPIIs of different K+ sensitivities
were targeted to various organelles and cellular subdomains
(Supplementary Fig. 11a) using approved targeting sequences and
basal FRET ratio signals were recorded in intact cells (Fig. 5d).
Average FRET ratio signals of the K+-insensitive lc-BON GEPII
1.0 were not affected by targeting (Supplementary Fig. 11b, c). In
contrast, FRET ratios of the K+-sensitive GEPII 1.0
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Fig. 4 Testing the functionality of recombinant GEPII 1.0 in vivo. a Schemes
showing the area of interest (musculus cremaster, arrow, upper panel) and
the mouse prepared for imaging using the 2-photon imaging device (lower
panel). b Representative in vivo FRET ratio signals of GEPII 1.0 loaded into
the cremaster tissue of a living mouse. Signals were imaged using a
2-photon ﬂuorescence imaging system at different z-positions. As indicated
10mM KCl was applied to the tissue during intravital microscopy and
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images showing the FRET signal (yellow, left images), mseCFP signal (blue,
middle images) and FRET ratio signal (pseudocolored, right images) of
GEPII 1.0 loaded into the musculus cremaster prior to (upper images) and
upon the addition of 10mM KCl (lower images) as indicated in b. White
scale bar in the lower right image represents 100 µm
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(Supplementary Fig. 11b, c) and lc-LysM GEPII 1.0 showed
organelle-speciﬁc differences with highest levels in the nucleus
and low levels within mitochondria (Fig. 5d and Supplementary
Fig. 11c). The differences of FRET ratio values between the
cytosol and nucleus were also observed in single cells expressing
non-targeted lc-LysM GEPII 1.0, which was equally distributed
within both compartments (Supplementary Fig. 11a, d). The
differences were equalized by membrane permeabilization (Fig. 5d
and Supplementary Fig. 11d). Under consideration that targeting
of GEPIIs does not cause any signiﬁcant artefacts, quantiﬁcations
of [K+]i in the different subcellular compartments revealed that in
diverse cell types the nuclear K+ ([K+]nuc) is always signiﬁcantly
higher than the cytosolic K+ concentration ([K+]cyto) (Fig. 5e)
with [K+]nuc/[K+]cyto ratios of 3.38, 1.94, 2.39, and 3.77 in HeLa,
INS-1, HEK293a, and EA.hy926 cells, respectively. In contrast,
targeted lc-LysM GEPII 1.0 revealed lower K+ concentrations
within mitochondria ([K+]mito) compared to [K+]cyto of living
cells (Fig. 5e) with [K+]mito/[K+]cyto ratios of 0.49, 0.42, 0.65, and
0.78 in HeLa, INS-1, HEK293a, and EA.hy926 cells, respectively.
Real-time visualization of intracellular K+ signals. To trigger
intracellular K+ alterations, we depolarized excitable INS-1 cells
and monitored [K+]cyto simultaneously with cytosolic Ca2+ con-
centration ([Ca2+]cyto) using lc-LysM GEPII 1.0 in combination
with CAR-GECO1, a far-red ﬂuorescent genetically encoded Ca2+
sensor (Fig. 6a). As already observed31, 32, [Ca2+]cyto transiently
increased in response to cell depolarization due to the activation
of voltage-gated Ca2+ channels. With a short delay after Ca2+
entry, the lc-LysM GEPII 1.0 signal clearly indicated a transient
reduction of [K+]cyto (Fig. 6a and Supplementary Fig. 12a).
Importantly, the FRET ratio signal of the high-sensitivity GEPII
1.0 (Supplementary Fig. 12b) as well as the K+-insensitive lc-BON
GEPII 1.0 (Supplementary Fig. 12c) remained unaffected under
these conditions. These results conﬁrm that lc-LysM GEPII 1.0
had indeed detected a change in intracellular K+ in real time. A
similar K+ signal was also observed upon depolarization of MIN6
cells (Supplementary Fig. 12d), another rodent pancreatic beta
cell line29. To further characterize the transient cytosolic K+
decrease, INS-1 cells were treated with tetraethylammonium
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Fig. 5 Characterization and application of GEPIIs in cells. a Representative pseudocolor ratio images of permeabilized HeLa cells expressing GEPII 1.0 in the
presence of different [K+]. Scale bar represents 20 µm. b CFP (cyan dashed line), FRET (yellow dashed line) ﬂuorescence intensities, and the respective
FRET ratio signal (black solid line) of GEPII 1.0 expressed in HeLa cells. Permeabilized (5 µM digitonin) HeLa cells were treated with different [K+] as
indicated using a semi-automatic perfusion system. c Normalized EC50 curves for K+ of different GEPIIs expressed in HeLa cells (n= 6 for each± SD). Cells
were permeabilized using 5 µM digitonin and respective K+ concentrations were added. Respective ΔFRET ratio values, normalized to the maximal
response, i.e., 100%, were plotted against [K+]. d Representative ratio images of HeLa cells expressing either cytosolic (upper panels), nuclear (middle
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cells for INS-1/n= 35 cells for HeLa/n= 184 cells for HEK293a/n= 49 cells for EA.hy.926), or mitochondria (n= 7 independent experiments for each/n=
142 cells for INS-1/n= 62 cells for HeLa/n= 102 cells for HEK293a/n= 45 cells for EA.hy926)
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chloride (TEA), a frequently used K+-channel blocker33, prior to
cell depolarization. When the cells were incubated with TEA, the
FRET ratio signal of cytosolic lc-LysM GEPII 1.0 gradually
increased, a sign that inhibition of plasma membrane K+ channels
induces accumulation of [K+]cyto (Supplementary Fig. 12e). TEA
did not affect the Ca2+ signal upon depolarization (Supplemen-
tary Fig. 12e), but the transient drop in [K+]cyto was strongly or
completely inhibited (Fig. 6b and Supplementary Fig. 12e).
We next tested the effects of inhibiting the cytosolic Ca2+
signal. This was done done in different ways: chelating
extracellular Ca2+ with EGTA (Fig. 6b and Supplementary
Fig. 12f), blocking voltage-gated Ca2+ channels with nifedipine
(Fig. 6b), and buffering intracellular Ca2+ elevations by BAPTA-
AM loading (Fig. 6b and Supplementary Fig. 12g). All of these
treatments considerably reduced the intracellular K+ transient in
response to cell depolarization. Taken together, these experiments
show that the GEPII K+ signal follows exactly the expected
pattern for the usual depolarization mechanism, in which Ca2+
entry via voltage-gated channels evokes activation of K+ channels,
followed by K+ efﬂux from the cells (Fig. 6c).
Finally, we investigated whether targeted lc-LysM GEPII 1.0
(Fig. 6d, upper panel) could be used to monitor subcellular K+
dynamics during cell depolarization. Despite almost identical
transient K+ signals in the cytosol and subplasmalemmal area,
[K+]nuc and [K+]mito were dynamically affected in a completely
different manner (Fig. 6d, lower panel). Though [K+]nuc was
higher than [K+]cyto, it exhibited a sustained reduction during
stimulation, while the low [K+]mito gradually increased in
response to cell depolarization (Fig. 6d). In this way, live-cell
imaging with targeted GEPIIs was able to detect the dynamic
organelle-speciﬁc K+ pools that are differently reshufﬂed in
response to cell activation.
Discussion
Based on Kbp we developed novel protein-based FRET probes,
the GEPIIs, that enable dynamic quantiﬁcation of biologically
relevant K+ variations in vitro, in situ, and in vivo. Both, muta-
tions of all acidic amino acids within the wild-type LysM domain
and the introduction of ﬂexible linkers between the BON and
LysM domain of Kbp signiﬁcantly decreased the K+ afﬁnity of
respective chimeras. While these rationally designed constructs
emerged suitable to image intra and extracellular K+ ﬂuctuations,
other strategies might further improve the characteristics of
Kbp-based GEPIIs in future. Already mutations of single acidic
amino acids within either the BON or LysM domain might sig-
niﬁcantly alter the K+ afﬁnity of the probe. In analogy to single
FP-based Ca2+ probes, the GECOs34, error-prone PCR, and site-
directed evolution approaches also have the potency to generate
improved GEPII variants. However, being already able to char-
acterize spatial and temporal changes of [K+] with the available
GEPIIs is a key to better understanding of K+-based signaling13,
which is so important in physiology1 and pathology3. Our data
demonstrate that recombinant GEPIIs can measure K+ levels in
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different body ﬂuids as precisely as ISE14. This can be done
conveniently in a conventional multi-well ﬂuorescence plate
reader and has the advantage of a very small sample volume
(around 5 µl) compared to common ISE instruments and most
other K+ indicators15, 16. This could enable more repetitive sam-
pling from small animals without sacriﬁcing them25, and could
also be useful in neonatal diagnostics35 and forensic medicine36.
We also demonstrated that an increase of [K+]ex upon cell death is
dynamically detectable in vitro and in situ with the GEPII-
technology. Also, uptake of K+ by proliferating bacteria can be
determined over time as a dynamic measure of cell viability and
proliferation rates. These ﬁndings are in line with other reports
that point to the importance of [K+]ex for cell growth17, 37.
Having established that GEPIIs can measure K+ accurately in
solution and in biological samples, we went on to explore their
usefulness in imaging applications. Intravital microscopy in the
striated muscle preparation of living mice showed that GEPIIs
can be used to follow spatiotemporal changes in [K+]ex in vivo.
These results suggest that GEPIIs could be used for dynamic
imaging of K+ ﬂuxes in the brain, similar to the methods already
established for Ca2+. However, calcium ions are not directly
involved in the generation of neuronal action potentials38; being
able to directly monitor [K+]ex in the living brain could be a great
step forward in our ability to study neuronal activity39.
We also applied GEPIIs to intracellular distribution of K+ in
organelles and subdomains of living cells using approved trans-
fection protocols. These experiments not only conﬁrmed the
feasibility of the method but also immediately yielded the inter-
esting results that [K+] is higher in the nucleus and lower in the
mitochondria than in the cytosol of several different cell types.
However, organelle targeting of ﬂuorescent probes can cause
artefacts due to differences in auto ﬂuorescence, viscosity, and
composition, which might produce false results. To exclude any
of these disturbances, we tested three different GEPIIs with same
FPs but different K+ afﬁnities within the different cellular com-
partments. Nevertheless the high [K+]nuc is surprising, as until
now there has been little evidence on the distribution of K+
within organelles, apart from studies from the 1970s40 and
1980s41 that indicated the existence of K+ gradients between the
cytosol and nucleus. K+ within the nucleus has been suggested to
contribute to the control of gene expression41, but although some
K+ channels and transporters are known to be present in the
nuclear envelope13, 42, the mechanisms that might dynamically
regulate [K+]nuc42 and [K+]mito42, 43 are not well understood.
Although nuclear pores allow the passage of macromolecules44,
their permeability for K+ ions remains elusive. Several studies45–
47 demonstrated that certain DNA structures speciﬁcally bind K+
with high afﬁnity, indicating a certain role of K+ within the
nucleus. However, further experiments are necessary to validate
any peculiarities of the K+ homeostasis of cellular nuclei.
By the usage of targeted GEPIIs, we are now also able to
visualize K+ accumulation within mitochondria in response to
Ca2+ elevation in individual cells in real time. Our ﬁndings
conﬁrm the assumption of concentration and electrical gradients
that facilitate K+ uptake by energized mitochondria42, 48. These
imaging experiments also tend to conﬁrm the existence of Ca2
+-activated K+ channels in the inner mitochondrial membrane
and reveal dynamic K+ changes in the organelle in pancreatic beta
cells. K+ imaging with GEPIIs will allow testing of diverse acti-
vators, inhibitors, and modulators of plasma membrane as well as
intracellular K+ channels in a practicable, high-throughput and
high-content manner. In conclusion, our results show that
GEPIIs expressed in living cells are a practical tool for further
investigating subcellular K+ dynamics, the mechanisms that
control them, and the consequences for cell signaling events and
related biological functions.
Methods
Chemicals and buffer solutions. Materials for cell culture were purchased from
PAA laboratories (Pasching, Austria). Restriction enzymes, chemically competent
10-beta Escherichia coli cells for cloning and chemically competent E. coli BL21
(DE3) cells for protein expression were obtained from New England Biolabs
(Ipswich, MA, USA). Agar–Agar Kobe I, CaCl2, CsCl, D-Glucose, EGTA, HEPES,
KCl, MgCl2, Monensin, NaCl, NaOH, NH3 (32%), RbCl, Triton X-100, Trypton/
Pepton and Yeast extract were purchased from Carl Roth (Graz, Austria). Agarose
was obtained from VWR International (Vienna, Austria). 1,2-Bis(2-aminophe-
noxy)Ethane-N,N,N′,N′-Tetraacetic Acid Tetrakis Acetoxymethyl Ester (BAPTA-
AM), 2-deoxy-D-glucose (2-DG), digitonin, gramicidin, nifedipine, N-methyl-D-
glucamine (NMDG), Oligomycin A, propidium iodide, and tetraethylammonium
chloride were obtained from Sigma Aldrich (Vienna, Austria). Bacterial protease
inhibitor cocktail containing AEBSF, E-64, Bestatin, EDTA, and Pepstatin was
purchased from Amresco (Cleveland, OH, USA).
Lysis buffer (in mM): 100 Na2HPO4, 200 NaCl, 10 imidazole, 250 units of
Benzonase Nuclease and bacterial Protease Inhibitor Cocktail, pH= 8.0. Washing
buffer (in mM) 100 Na2HPO4, 200 NaCl, 40 Imidazole, pH 8.0. Puriﬁcation buffer
(in mM): 100 Na2HPO4, 200 NaCl, 200 imidazole, pH 8.0. Elution buffer (in mM):
10 HEPES ±0.05% Triton X-100, pH 7.3 with NMDG. Characterization of GEPIIs
in vitro was performed using elution buffer with different ions added. EC50s in situ
were determined using the following buffers containing different molarities of KCl,
10 mM HEPES and NMDG to a ﬁnal molarity of 150 mM, pH adjusted to 7.4.
Buffer containing 300 mM K+ consisted of (in mM) 300 KCl, 10 HEPES, pH 7.4
with NMDG. Hemoglobin determination in murine sera was performed using
drabkin’s solution. Assay buffer for cell viability experiments was composed of (in
mM) 143 NaCl, 2 CaCl2, 1 MgCl2, 10 HEPES either with 10 mM D-Glucose or 10
mM 2-DG. Before ﬂuorescence microscopy experiments, cells were washed and
stored for 30 min in a HEPES-buffered solution (storage buffer) containing 138
mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 2.6 mM
NaHCO3, 0.44 mM KH2PO4, 0.34 mM Na2HPO4, 10 mM D-glucose, 0.1% vitamins,
0.2% essential amino acids, and 1% penicillin–streptomycin, pH adjusted to 7.4
with NaOH. Buffers used for physiological measurements contained (in mM): 138
NaCl, 5 KCl, 1 MgCl2, 10 D-glucose and 10 HEPES, either with 2 CaCl2 (Ca2+
buffer), 1 EGTA (Ca2+ free buffer) or ±0.1 nifedipine or 15 tetraethylammonium
chloride. Depolarization buffer was composed of (in mM): 73 NaCl, 70 KCl, 1 mM
MgCl2, 10 D-glucose and 10 HEPES, either with 2 CaCl2 (depolarizing Ca2+ buffer),
1 EGTA, or ±0.1 nifedipine or 15 tetraethylammonium chloride.
Cloning of GEPIIs. Cloning was performed according to conventional restriction
digestion based procedures and all products were veriﬁed by sequencing (Euroﬁns
Genomics, Munich, Germany). Primers used for DNA ampliﬁcation (Supple-
mentary Table 3) were purchased from Thermo Fisher Scientiﬁc (Vienna, Austria).
Genomic DNA of E. coli 10-beta served as PCR template to isolate Kbp from
bacterial cells. Single nucleotide exchanges to receive lc-BON GEPII 1.0 were
performed using the primers: lc-BON 01-05 fwd and Kbp rev primer. Lc-LysM
GEPII 1.0 was generated using lc-LysM 01 and 02 rev primers, and Kbp for. To
obtain GEPII 2.7, GEPII 2.10 and GEPII 2.15 the primers GEPII 2.7 for/ rev, GEPII
2.10 for/ rev and GEPII 2.15 for/ rev, in combination with Kbp fwd/ rev were used.
Mitochondrial targeting of GEPIIs was achieved by a tandem dimeric repeat of
COX VIII targeting sequence at the N-terminal end. For nuclear targeting, the class
III nuclear localization signal KRSWSMAFC was added via the primers cpV fwd
and NLS cpV rev, or to observe cytosolic localization, the lysine rich motif
LPPLERLTL derived from GP41 from human immunodeﬁciency virus was fused
via the primers cpV fwd and NES cpV rev. GEPIIs were attached to the inner leaﬂet
of the plasma membrane using the the K-ras-derived CAAX-motife
MSKDVKKKKKKSKTKCVIM with CAAX cpV rev primer.
Protein expression and puriﬁcation. Recombinant expression of GEPIIs was
performed using pETM-11 bacterial expression vectors. Proteins were expressed in
E. coli BL-21 (DE3) cells. At an OD600 of 0.8, protein expression was induced by
adding 1 mM β-D-1-thiogalactopyranoside (IPTG) and cells were incubated at
room temperature. After 4 h cells were pelleted and cells were re-suspended in 20
ml of lysis buffer. Then cells were lysed by sonication and cleared by centrifugation.
Proteins were puriﬁed using a 5 ml HisTrap column (GE Healthcare, Vienna,
Austria) for immobilized metal afﬁnity chromatography on an ÄKTA pure system
(GE Healthcare, Vienna, Austria) at room temperature. HisTrap columns were
equilibrated using lysis buffer, E. coli lysates were applied on the columns and
washed with washing buffer. Proteins were eluted with puriﬁcation buffer and the
His6-Protein A tag was cleaved overnight at 4 °C using 2% (w/w) of 1 mgml-1
recombinant His-tagged TEV protease. Processed proteins were re-puriﬁed from
the fusion tags and TEV protease at room temperature using size exclusion col-
umns (16/600 200 pg, GE Healthcare) on an ÄKTA pure system (GE Healthcare).
Subsequently proteins were eluted using elution buffer.
Characterization of puriﬁed GEPIIs. Puriﬁed GEPIIs were analyzed using the
CLARIOstar ﬂuorescent plate reader (BMG Labtech, Ortenberg, Germany). For
GEPII characterization, black CELLSTAR 96-well cell culture microplates (PS,
F-Bottom, Greiner Bio-One, Kremsmünster, Austria) were used. Permanently,
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GEPIIs at a ﬁnal concentration of 200 nM were analyzed. Spectra were recorded
using excitation at 413.4 nm± 8 nm, No. of single recorded wavelength points: 121,
Emission from 441.4 to 561.4 nm in steps of 1 nm± 5 nm, Gain: 2000, focal height
adjusted to blank. Recorded spectra were analyzed using GraphPad Prism 5
Software (GraphPad Software, Inc., La Jolla, CA, USA), equalized for area under
curve and smoothed using 6th order polynomial, averaging 6 neighbors on each
side. EC50 values and speciﬁcity of GEPIIs was assessed performing single point
scans using the ﬂuorescence multichromatic mode of BMG Analysis software with
the following standardized settings: Excitation 430 nm± 10 nm, Emissions: 475
nm± 5 nm and 525 nm± 5 nm. Dichroic ﬁlters used: 455 and 480 nm, Gain: 2000,
focal height adjusted to blank. Data was calculated dividing emissions 525/475 nm
and ratio values were shown as difference from blank (0 mM [ion]). The pH
stability of GEPII 1.0 was determined using Elution buffers with pH adjusted from
5.5 to 10.0. Kinetics of K+ binding by GEPII 1.0 was assessed using F 4500
ﬂuorescence spectrophotometer (Hitachi). Reversibility of K+ binding by GEPII 1.0
was determined by embedding GEPII 1.0 in 0.5% agarose and performing ﬂuor-
escence microscopic analysis in combination with a gravity-based perfusion system
(NGFI, Graz, Austria).
Animals. For all experiments, male C57BL/6J mice obtained from Charles River
Laboratories (Sulzfeld, Germany) were used. Mice were maintained in a clean
environment with a regular light–dark cycle (12 h/12 h) and unlimited access to
Chow or Western-type diet (WTD; 21% fat, 0.2% cholesterol; Ssniff Spezialdiaeten
GmbH, Soest, Germany) and water. Blood was collected by either retro-bulbar or
V. facialis puncture and serum was prepared by centrifugation for 10 min at 400 rcf
(Himac CT15RE, Hitachi, Dusseldorf, Germany). To receive the bile from the
animals, mice were sacriﬁced by cervical dislocation. Gallbladders were removed
and centrifuged for 15 min at 400 rcf to release the bile (Himac). Urine was
collected from mice fed WTD for 20 weeks after cervical dislocation by direct
aspiration from bladders using syringe and needle. Animal experiments were
carried out in accordance with the European Directive 2010/63/EU and approved
by the Federal Ministry of Science, Research, and Economy, Vienna, Austria.
Ischemia Reperfusion Injury was induced in anesthetized mice. Taking care of
intestines, bowel and vasculature, microvascular clamps were applied to both renal
pedicles for 25 min. During surgery mice were hydrated and body temperature was
kept at ∼37 °C using an adjustable heating pad. As a control, non-operated healthy
mice were used.
Assessment of clinical renal injury parameters. Biochemical analysis included
serum urea and creatinine (Roche Diagnostics, Mannheim, Germany). Serum
neutrophil gelatinase-associated lipocalin (Lipocalin-2) was evaluated using a
commercially available enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN, USA). Measurements were performed using a FLUOstar Omega
photometer (BMG Labtech, Ortenberg, Germany).
Histology. Formalin ﬁxed parafﬁn embedded kidney tissue of healthy mice and
mice after IRI was sectioned at 4 µm and stained with Periodic Acid-Schiff (Sigma-
Aldrich) using a standard protocol. Finally, slides were dehydrated, cleared and
mounted in anhydrous mounting medium Roti-Histokitt II (Carl Roth). Stainings
were evaluated for the number of tubular casts in six high power ﬁelds (HPFs) by
one blinded examiner.
K+ determination using ISE in human blood and urine samples. A pilot study
enrolling 15 patients on maintenance hemodialysis (HD) recruited from the dia-
lysis ward of the Clinical Division of Nephrology, Medical University of Graz and
15 healthy participants without any documented kidney disease was performed.
The study protocol was approved by the Internal Review Board of the Medical
University of Graz (EK-Number: 29-223 ex 16/17). An informed consent was
signed by all participants before enrollment. Blood and urine samples from healthy
participants were collected during an ambulatory visit with blood collection syr-
inges (BD A-Line, Plymouth, UK) and separator tubes (Greiner Bio-One, Vacu-
ette). Both were coated with lithium-heparin. Blood samples from HD-Patients
were obtained before the start of their regular hemodialysis treatment.
Spontaneous midstream urine of healthy individuals was collected in urine
tubes (Greiner Bio-One, Vacuette) without any pre-analytic additives. Participants
were not asked to be fasting at the time of sampling. Potassium levels within the
urine and serum of healthy donors were determined using ion sensitive electrodes
(Cobas 8000, Roche diagnostics, Vienna, Austria) with indirect potentiometry as
test principle. Serum samples of HD patients were analyzed for K+ using ion
sensitive electrode (ABL 800 Flex, Drott, Vienna, Austria).
Determination of K+ within bodily ﬂuids using GEPII 1.0. K+ levels in biological
samples were assessed using a calibration curve. Measurements were performed
using standard CLARIOstar setup. The equation received was solved for x and
applied to calculate the [K+] in mMol L−1 within biological samples, according to
the formula:
Kþ½  mMol
L
 
¼ ΔR 1:2050:03651 1:205 0:002938ð Þ
Dilution
1000
:
Assessment of K+ levels in biological samples was performed diluting the
samples with elution buffer. Additionally, murine sera were analyzed for
Hemoglobin (Hb) content using drabkin’s reagent and [K+] were corrected for
hemolysis assuming a linear correlation between increasing Hb and increasing
[K+].
GEPII 1.0 based cell growth and cell death assay. INS-1 832/13 (INS-1) cells
were seeded one day before the experiment and showed 80–100% conﬂuency at day
of analysis. Analyses of supernatant were performed using the standard CLAR-
IOstar protocol. Cells were permeabilized using 50 µM digitonin. Measurements at
the micsoscope were performed at an iMic inverted and advanced ﬂuorescent
Microscope (TILL Photonics, Graeﬂing, Germany). Cells were seeded the day
before the experiments in 96 well µ-plates (ibidi, Munich, Germany) and analyzed
at different conﬂuences ranging from 30 to 100%. Cells were permeabilized at time
point indicated by application of 30 µM digitonin. Experiments were performed
using an ×20 magniﬁcation objective (alpha Plan Fluor ×20, Zeiss, Göttingen,
Germany) with a motorized sample stage (TILL Photonics, Graeﬂing, Germany).
For illumination a Polychrome 5000 (TILL Photonics) was used. Emissions were
recorded using a charged coupled device camera (AVT Stringray F145B, Allied
Visions Technologies, Stadtroda, Germany). Filter set was obtained from AHF
Analysentechnik (Tubingen, Germany). FRET-based GEPII measurements were
performed at an excitation of 430 nm and emissions were collected simultaneously
at 480 and 535 nm using an optical beam-splitter (Dichroic 69008-ET-ECFP/
EYFP/mCherry for CFP/YFP). Alternately, FRET and mseCFP emissions, and
bright ﬁeld images were acquired.
Bacterial growth experiments were performed using LB medium. 1.85*109 E.
coli cells were seeded in 39 ml at t= 0 and cultured for 12 h at 37 °C vigorously
shaking. Directly, after 4, 8, and 12 h and 1 additional hour at 75 °C or with 50 mg
L−1 Kanamycin, 100 mg L−1 Ampicillin, or 50 µM Gramicidin suspensions were
analyzed regarding OD600 and 1 ml of supernatant was centrifuged at 600 rcf for
10 min (Himac) to pellet bacterial cells. Supernatant was taken, 1 vol of 30 mM
NMDG containing solution was added and mixture was heated to 95 °C for 20 min
to remove NH4+ from the sample and to inactivate proteases. After centrifugation
at 9500 rcf for 20 min (Himac) supernatant was diluted and [K+] concentrations
within the samples were calculated.
Propidium iodide (PI) staining of bacteria was performed using PI (Sigma-
Aldrich) at a ﬁnal concentration of 1 µg mL−1 in PBS. PI stained cells were
transferred into CELLSTAR 96-well plates PS, F-Bottom (Greiner Bio-One) and
ﬂuorimetric analysis was performed using the CLARIOstar ﬂuorescence plate
reader. PI staining solution without bacteria served as blank. Excitation was set at
535 nm± 10 nm, emission was collected at 617 nm± 5 nm. Dichroic ﬁlters used:
576 nm, Gain: 2000, focal height adjusted to blank.
Two-photon microscopy. Surgical preparation of the cremaster muscle was per-
formed as originally described49 in with minor modiﬁcations50. Mouse experi-
ments were performed according to German legislation for the protection of
animals and approved by the Regierung von Oberbayern, München, Germany.
Brieﬂy, male mice were anesthetized with an i.p. administration of ketamine/
xylazine (100 mg kg−1 ketamine, 10 mg kg−1 xylazine). The right cremaster muscle
was excised by a ventral incision of the scrotum, opened ventrally and spread over
the pedestal of a custom-made microscopy stage. The body temperature was
maintained at 37 °C using a heating pad placed under the mouse. Throughout the
procedure, as well as after surgical preparation during in vivo microscopy, the
muscle was superfused with warm buffered saline. In vivo imaging was performed
using a Zeiss LSM 7MP microscope, equipped with a Ti:Sa laser (Chameleon
Vision II, Coherent, Dieburg, Germany). Excitation wavelength was 810 nm. Light
from the specimen was collected with a W-Plan-Apochormat ×20/1.0 objective
(Zeiss) and detected by two LSM BIG Detectors at 460–500 and 520–560 nm. For
tissue loading with GEPII 1.0, recombinant GEPII 1.0 was added into the muscle
bath for 20 min (1:10 dilution) at a concentration of 4 µM. Measurements were
conducted at 20, 70, and 130 µm depth in the muscle tissue at the indicated time
points.
Cell culture and transfection. DMEM (Sigma Aldrich) containing 10% fetal
bovine serum, 100 Uml−1 penicillin, 100 μg gn−1 streptomycin, and 2.5 µg ml−1
Fungizone (Thermo Fisher Scientiﬁc) was used to grow EA.hy926, HeLa and
HEK293a cells (all obtained from ATCC, Guernsey, UK). INS-1 cells were obtained
from C.B. Newgard, Department of Pharmacology and Cancer Biology, Duke
University School of Medicine, USA. INS-1 cells were cultivated in GIBCO RPMI
Medium 1640 obtained from Thermo Fisher Scientiﬁc, additionally supplemented
with 10% FCS, 10 mM HEPES, 1 mM Sodium pyruvate, 0.05 mM
2-mercaptoethanl, 100 Uml−1 penicillin, 100 μg gn−1 streptomycin and 2.5 µg ml−1
Fungizone (Thermo Fisher Scientiﬁc). Transfection of cells in 30-mm imaging
dishes was performed using TransFast transfection reagent (Promega GmbH,
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Mannheim, Germany)51. To load cells with BAPTA-AM, culture media was
removed from cells and replaced with 37 °C warm nominally Ca2+ free buffer
containing 50 µM of BAPTA-AM directly before ﬂuorescence microscopic
experiments. Cells were stored for 45 min in a humidiﬁed incubator (37 °C, 5%
CO2). Excessive BAPTA-AM was removed by washing steps with 37 °C warm
nominally Ca2+ free buffer.
Live cell imaging. Prior to the measurements cells were equilibrated in storage
buffer for 30 min. During the experiment, buffers were exchanged using a ﬂow
chamber, connected to a gravity-based perfusion system (NGFI, Graz, Austria) and
a vacuum pump (Chemistry diaphragm pump ME 1c, Vacuubrand, Wertheim,
Germany). Fluorescence microscopic experiments were performed at an iMic
inverted and advanced ﬂuorescent Microscope using an ×40 magniﬁcation objec-
tive (alpha Plan Fluor ×40, Zeiss, Göttingen, Germany) with a motorized sample
stage (TILL Photonics, Graeﬂing, Germany)21. Ca2+ imaging using Car-GECO1
was performed at an excitation of 575 nm and emission was collected at 600 nm.
For control and acquisition the software Live acquisition 2 (TILL Photonics) was
used. Subcellular targeting of GEPIIs was ensured using an array confocal laser
scanning microscope (ACLSM)31. Targeted GEPIIs were illuminated using 488 nm
laser light and emission was collected at 535 nm at a binning of 2 using a CCD
camera (CoolSnap HQ2, Photometrics, Tucson, Arizona, USA).
Data analysis. Analysis of raw data acquired was performed using excel (Micro-
soft, Washington, US) in combination with GraphPad Prism5 software (GraphPad
Software). Bleaching correction of live cell imaging data was performed by curve
ﬁtting. Representative ratio images were created using MetaMorph microscopy
automation and image analysis software (Molecular Devices, Sunnyvale, CA, USA).
Background correction was performed and FRET and mseCFP images were divided
with appropriate set ratio range. Statistical analysis of data was performed using
GraphPad Prism5 software, either performing paired t-test, unpaired t-test or one-
way ANOVA test with Tukey’s Multiple Comparison Test as indicated in the ﬁgure
legends.
Data availability. Original data are available from the corresponding author upon
reasonable request.
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